Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Pharma-Bio Serv (PBSV) over the last 16 years, with Q4 2025 value amounting to $3.4 million.

  • Pharma-Bio Serv's Cash & Equivalents fell 5006.6% to $3.4 million in Q4 2025 from the same period last year, while for Oct 2025 it was $3.4 million, marking a year-over-year decrease of 5006.6%. This contributed to the annual value of $3.4 million for FY2025, which is 5006.6% down from last year.
  • Pharma-Bio Serv's Cash & Equivalents amounted to $3.4 million in Q4 2025, which was down 5006.6% from $4.0 million recorded in Q3 2025.
  • In the past 5 years, Pharma-Bio Serv's Cash & Equivalents registered a high of $19.0 million during Q1 2021, and its lowest value of $2.1 million during Q2 2025.
  • Its 5-year average for Cash & Equivalents is $9.7 million, with a median of $7.7 million in 2023.
  • Per our database at Business Quant, Pharma-Bio Serv's Cash & Equivalents plummeted by 7984.68% in 2023 and then soared by 12721.7% in 2024.
  • Pharma-Bio Serv's Cash & Equivalents (Quarter) stood at $17.5 million in 2021, then fell by 17.21% to $14.5 million in 2022, then fell by 27.77% to $10.4 million in 2023, then tumbled by 35.22% to $6.8 million in 2024, then plummeted by 50.07% to $3.4 million in 2025.
  • Its Cash & Equivalents stands at $3.4 million for Q4 2025, versus $4.0 million for Q3 2025 and $2.1 million for Q2 2025.